NCT00994331

Brief Summary

The Stereotaxis Niobe® II Magnetic Navigation System (MNS) is designed to direct and digitally control catheter and guidewire based therapeutic and diagnostic devices along complex trajectories within the heart and coronary vasculature. Navigation using vectors acquired from the CT Co-registration feature of Navigant™ provides clinical benefits for percutaneous coronary intervention (PCI) by decreasing the amount of contrast used during complex PCI procedures.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4

participants targeted

Target at below P25 for not_applicable coronary-artery-disease

Timeline
Completed

Started Oct 2009

Shorter than P25 for not_applicable coronary-artery-disease

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2009

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

October 9, 2009

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 14, 2009

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2011

Completed
Last Updated

March 10, 2011

Status Verified

March 1, 2011

Enrollment Period

1.4 years

First QC Date

October 9, 2009

Last Update Submit

March 8, 2011

Conditions

Keywords

Percutaneous Coronary InterventionMagnetic NavigationComputed Tomography

Outcome Measures

Primary Outcomes (1)

  • The primary endpoint is to compare and evaluate the total contrast use between Groups A, B and C .

    6 months

Secondary Outcomes (1)

  • The secondary endpoint is to compare and evaluate the following data points between Groups A, B and C: fluoroscopy time, procedure time, crossing time, procedural contrast use, adverse events (AEs): e.g. clinically significant perforations

    6 months

Study Arms (3)

Group A-CT Coregistration

ACTIVE COMPARATOR

5 subjects with CT co-registration in a magnetically navigated PCI (Group A)

Procedure: Percutaneous coronary intervention

Group B-Angiographic

ACTIVE COMPARATOR

5 subjects with angiographic co-registration in a magnetically navigated PCI (Group B)

Procedure: Percutaneous coronary intervention

Group C-Standard Angiography

ACTIVE COMPARATOR

5 subjects with standard angiography in a conventional PCI (Group C)

Procedure: Percutaneous coronary intervention

Interventions

non surgical procedure to open blocked coronary arteries

Group A-CT CoregistrationGroup B-AngiographicGroup C-Standard Angiography

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients must be between 18-80 years of age
  • Willing and able to provide prior written informed consent
  • Patients present with a single bifurcated lesion or single non-CTO complex lesion requiring PCI.
  • Able to be safely exposed to magnetic fields, such as magnetic resonance imaging (MRI)
  • CT angiography performed prior to cardiac catheterization (must be performed \>48 hours prior to procedure to limit peri-procedural contrast use, but \<12 months prior to the procedure)

You may not qualify if:

  • Patients with a creatinine greater than 2.0 mg/dL
  • Exclude patients whom in the Investigator's opinion, are hemodynamically unstable on the day of the procedure.
  • Untreatable allergy to contrast media
  • Patients who have undergone CT angiography within 48 hours of index PCI procedure
  • Patients with chronic total occlusions (CTOs) requiring intervention.
  • Patients requiring treatment for lesions other than the single bifurcated or single non-CTO complex lesion.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

New York Presbyterian Hospital-Columbia Medical Center

New York, New York, 10032, United States

Location

MeSH Terms

Conditions

Coronary Artery Disease

Interventions

Percutaneous Coronary Intervention

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Intervention Hierarchy (Ancestors)

Endovascular ProceduresVascular Surgical ProceduresCardiovascular Surgical ProceduresSurgical Procedures, OperativeMinimally Invasive Surgical Procedures

Study Officials

  • Jeffrey Moses, MD

    New York Presbyterian Hospital-Columbia Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

October 9, 2009

First Posted

October 14, 2009

Study Start

October 1, 2009

Primary Completion

March 1, 2011

Study Completion

March 1, 2011

Last Updated

March 10, 2011

Record last verified: 2011-03

Locations